HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today confirmed that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company’s Abbreviated New Drug Application (ANDA) for generic version of Depakote® (divalproex ER) 250mg Extended-release Tablets. The Company also received tentative approval on the 500mg tablets and expects to receive final approval on August 3, 2009, upon expiration of the 180-day exclusivity period. Abbott Laboratories markets Depakote® ER for the treatment of epilepsy and bipolar disorders.
